EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 January 2023
EMA/CHMP/15748/2023
Human Medicines Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Dupixent (dupilumab)	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s)in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	Sanofi Winthrop Industrie 82 Avenue Raspail 94250 Gentilly FRANCE

Procedure	
Procedure number:	EMEA/H/C/004390/II/0060

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan P/0329/2021. All studies in the agreed paediatric investigation plan P/0329/2021 were conducted after the entry into force of that Regulation,

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan P/0329/2021 is included in the technical dossier.